Main Article Content
Background: Mineral bone disease (MBD) is a common complication in patients with chronic kidney disease (CKD). The objective of this study is to determine the prevalence and characteristics of CKD-MBD among adult patients with CKD attending the University of Port Harcourt Teaching Hospital.
Methods: One hundred and fifty subjects with chronic kidney disease patients who fulfilled the inclusion criteria for this study were recruited. Patients had a detailed clinical assessment, biochemical and radiological evaluations for CKD-MBD. Biochemical investigations included serum calcium, phosphate, parathyroid hormone (PTH) and alkaline phosphatase.
Results: The age range of the patients was 22-80 years, with a mean of 45.1 (±11.9) years. There were 90 males and 60 females with male to female ratio of 1.5:1. The prevalence of CKD-MBD in the study population was 55.3%. Of this, sixty one (73.5%) patients had low turnover bone disease while 22 (26.5%) patients had high turnover bone disease. The mean values for serum PTH, serum calcium, serum phosphate, alkaline phosphatase and caxpo 4 product among the CKD-MBD patients were 205.06±112.6 pg/ml, 2.56±0.73 mmol/l, 1.63±0.63 mmol/l, 109.26±65.57I U/L and 4.07±1.28 mmol2/l2 respectively but the values among non CKD-MBD patients were 123.08±120.99 pg/ml, 2.32±0.46 mmol/l, 1.54±0.57 mmol/l, 108.13±51.84I U/L and 3.52±1.32 mmol2/l2 respectively.
Conclusion: The prevalence of CKD-MBD in our environment is high and low turnover bone disease is the commonest type.
Beaglehole R, Yach D. Globalization and the prevention and control of non-communicable disease. The neglected chronic kidney disease of adult. Lancet. 2003;362:903-8.
Atkins RC. The changing patterns of chronic kidney disease: the need to develop strategies for prevention relevant to different regions and countries. Kidney Int Suppl. 2005;98:83-5.
K/DOQI clinical practice guideline for chronic kidney disease: Evaluation, classification, stratification. Part IV: Definition and classification of stages of chronic kidney disease. Am J Kidney Dis. 2002;39:546-75.
Arogundade FA, Barsoum RS. CKD prevention in sub-Saharan Africa: A call for government, non-government and community support. Am J Kidney Dis. 2008;51:515-23.
Pugsley D, Norris KC, Garcia-Garcia G, Agodoa L. Global approaches for understanding the disproportionate burden of chronic kidney disease. Ethn Dis. 2009; 19:1-2.
National Kidney Foundation. K/DOQI clinical practice guideline for chronic kidney disease: Evaluation, classification and stratification. Am J Kid Dis. 2002;39: 1-226.
Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int. 2014;85(1):142–150.
Kadiri S. Towards reducing the impact of chronic kidney disease. African Health. 2001;23:9-10.
Kadiri S, Arijie A. Temporal variations and metrological factors in hospital admission of chronic renal failure in South-south Nigeria. West Afri J Med. 1999;18:49-51.
El Nahas M, Bello AK. Chronic Kidney Disease: The global challenge. Lancet. 2005;365:331-40.
Onyemekeihia R. Renal osteodystrophy in Benin. A dissertation submitted to the National Postgraduate Medical College of Nigeria, Faculty of Internal Medicine. 2004;56.
Sanusi AA, Arogundade FA, Oladigbo M. Prevalence and pattern of renal bone disease in end stage renal disease patients in IIe-Ife, Nigeria. West Afri J Med. 2010;29:75-80.
Abd ElHafeez S, Bolignano D, D’Arrigo G, et al. Prevalence and burden of chronic kidney disease among the general population and high-risk groups in Africa: A systematic review BMJ Open. 2018;8: e015069.
Amira CO, Bello BT, Braimoh RW. Chronic kidney disease: A ten-year study of aetiology and epidemiological trends in Lagos, Nigeria. British Journal of Renal Medicine. 2015;19(4):19-22.
Kidney Disease: Improving Global Outcome (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD). Kidney Int Suppl. 2009;76(113);S1-130.
Waziri B, Duarte R, Naicker S. Biochemical markers of mineral bone disorder in South African patients on maintenance haemodialysis. Afri Health Sci. 2017;17(2): 445-452.
Kore C, Yohannes HM. Prevalence of chronic kidney disease and associated factors among patients with kidney problems public hospitals in addis Ababa, Ethiopia. J Kidney. 2018;4:162.
Ifeoma I. Ulasi, Chinwuba K. Ijoma, The enormity of chronic kidney disease in Nigeria: The situation in a teaching hospital in South-East Nigeria. Journal of Tropical Medicine. 2010;501957.
Amoako YA, Laryea DO, Bedu-Addo G, Andoh H, Awuku YA. Clinical and demographic characteristics of chronic kidney disease patients in a tertiary facility in Ghana. Pan Afr Med J. 2014; 18:274.
Ando M, Yanagisawa N. Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus infected patients. World J Nephrol. 2015;4(3):388–395.
Okoye JU, Arodiwe EB, Ulasi II, Ijoma CK, Onodugo OD. Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria. Afr Health Sci. 2015;15(3):941–948.
Ahmed HA, Elzorkany KM, Yasein YS, Abd-Elsattar Saif AF. Prevalence of mineral bone disorders among hemodialysis patients in Menoufia Governorate, Egypt. Menoufia Med J. 2017;30:687-92.
Agarwal SK. Assessment of renal bone mineral disorder in naïve CKD patients. A single centre prospective study. Indian J Nephrol 2007;17:96-100.
London G, Coyne D, Hruska K, Malluche HH, Martin KJ. The new Kidney Disease: Improving Global Outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Clin Nephrol. 2010;74(6):423–432.